Public Comments Favoring CMS Coverage of Warfarin PGx Dosing May Not Be Enough

Payor groups, professional organizations, academia, industry, healthcare providers, patient advocates, and patients were among 70 respondents to a CMS-issued national coverage-assessment notice seeking to determine whether the government payor should cover pharmacogenomic-guided warfarin testing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories